Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mo | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
16.06. | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
16.06. | NLS Pharmaceutics Ltd.: NLS Pharmaceutics CEO Issues Letter to Shareholders | 801 | PR Newswire | ZURICH, June 16, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP), a Swiss clinical-stage biopharmaceutical company focused on developing innovative... ► Artikel lesen | |
06.06. | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
NLS PHARMACEUTICS Aktie jetzt für 0€ handeln | |||||
21.05. | NLS Pharmaceutics präsentiert Mazindol-Studie auf ASCP-Tagung | 2 | Investing.com Deutsch | ||
21.05. | NLS Pharmaceutics to present Mazindol study at ASCP Meeting | 2 | Investing.com | ||
16.05. | NLS Pharmaceutics Ltd. - 20-F, Annual and transition report of foreign private issuers | 1 | SEC Filings | ||
05.05. | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
24.04. | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
15.04. | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
15.04. | NLS Pharmaceutics Ltd.: NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal Models | 247 | PR Newswire | Non-opioid, multi-mechanism profile positions Mazindol as a differentiated asset in addiction therapeutics
Favorable results support potential expansion into high-value... ► Artikel lesen | |
31.03. | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
31.03. | NLS Pharmaceutics AG: NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement | 444 | ACCESS Newswire | The equity financing is at a 10% premium to the market share price1 ZÜRICH, SWITZERLAND / ACCESS Newswire / March 31, 2025 / NLS Pharmaceutics Ltd.(NASDAQ:NLSP) ("NLS" or the "Company"), a Swiss clinical-stage... ► Artikel lesen | |
10.03. | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
10.03. | NLS Pharmaceutics kündigt Fusion mit Kadimastem an | 2 | Investing.com Deutsch | ||
27.02. | NLS Pharmaceutics reports progress in narcolepsy treatment | 1 | Investing.com | ||
27.02. | NLS Pharmaceutics Ltd.: NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform | 268 | PR Newswire | ZÜRICH, Switzerland, Feb. 27, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP) (Nasdaq: NLSPW) ("NLS" or the "Company"), in collaboration with Aexon... ► Artikel lesen | |
25.02. | NLS Pharmaceutics Ltd.; Kadimastem Ltd.: Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment | 309 | PR Newswire | Companies Advance Collaborative Clinical Development of iTOL-102: A Potential Cure for Diabetes Without the Need for Chronic Life-long Immune Suppression ZURICH and NESS ZIONA, Israel... ► Artikel lesen | |
25.02. | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
10.02. | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
REGENCELL BIOSCIENCE | 24,000 | +131,66 % | Regencell Bioscience Stock Soars 140% | ||
SUMMIT THERAPEUTICS | 24,610 | +8,80 % | Astrazeneca vor Milliarden-Partnerschaft mit Summit Therapeutics - Agentur | DJ Astrazeneca vor Milliarden-Partnerschaft mit Summit - Agentur
DOW JONES--Astrazeneca sichert sich möglicherweise mit einem Milliardendeal Zugang zu einem Krebsmedikament. Der britische Pharmakonzern... ► Artikel lesen | |
BIONTECH | 94,90 | +1,50 % | BioNTech-Aktie: Merkwürdiges Kursverhalten | © Foto: SymbolbildDer steinige Weg vom Corona-Helden zum Krebs-Jäger. So hätte auch die Überschrift lauten können, denn die Mainzer sorgen derzeit für Aufsehen mit Übernahmen und Kooperationen. Einmal... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 5,305 | +1,82 % | What Analysts Are Saying About Recursion Pharmaceuticals Stock | ||
QIAGEN | 40,850 | -0,07 % | Dividendenbekanntmachungen (02.07.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AECOM US00766T1007 0,26 USD 0,2202 EUR AMADEUS IT GROUP SA ES0109067019 - 0,89 EUR ASSECO SOUTH EASTERN EUROPE SA PLASSEE00014 1... ► Artikel lesen | |
CG ONCOLOGY | 27,055 | +1,41 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates | - Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signal... ► Artikel lesen | |
EVOTEC | 7,180 | +0,56 % | Aurubis, BASF, Evotec, Redcare Pharmacy, ThyssenKrupp, Zalando - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
LIXTE BIOTECHNOLOGY | 2,725 | +34,90 % | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | ||
VERVE THERAPEUTICS | 11,245 | +0,31 % | BMO downgrades Verve Therapeutics saying Lilly buyout deal caps upside | ||
VOR BIOPHARMA | 1,940 | +33,79 % | Vor Biopharma: Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., July 01, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, effective... ► Artikel lesen | |
SANA BIOTECHNOLOGY | 3,170 | +8,56 % | Morgan Stanley initiates Sana Biotechnology stock with Overweight rating | ||
QUANTUM-SI | 2,140 | +8,08 % | Quantum-Si stock falls after pricing capital raise of $50M via stock offering | ||
INSTIL BIO | 27,360 | +14,91 % | Instil Bio: Kaufgelegenheit nach Rücksetzer? | Mit der Aktie von Instil Bio feierten Mitglieder des No Brainer Club im vergangenen Jahr einen echten Tenbagger. Nach dem Kursrücksetzer der vergangenen Tage könnte der Titel erneut von Interesse sein.... ► Artikel lesen | |
KINIKSA PHARMACEUTICALS | 27,710 | +0,91 % | Kiniksa Pharmaceuticals: A 7.9 Score and Room for Growth | ||
ARCUTIS BIOTHERAPEUTICS | 13,840 | +0,58 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | WESTLAKE VILLAGE, Calif., July 03, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations... ► Artikel lesen |